Matthew L. Sherman
2021 - Deciphera Pharmaceuticals
Compensation breakdown
Non-Equity Incentive Plan | $189,067 |
---|---|
Option Awards | $2,103,820 |
Salary | $525,185 |
Stock Awards | $632,922 |
Other | $11,600 |
Total | $3,462,594 |
Sherman received $2.1M in option awards, accounting for 61% of the total pay in 2021.
Sherman also received $189.1K in non-equity incentive plan, $525.2K in salary, $632.9K in stock awards and $11.6K in other compensation.
Rankings
In 2021, Matthew L. Sherman's compensation ranked 3,869th out of 12,415 executives tracked by ExecPay. In other words, Sherman earned more than 68.8% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 3,869 out of 12,415 | 69th |
Division Manufacturing | 1,584 out of 5,508 | 71st |
Major group Chemicals And Allied Products | 648 out of 2,378 | 73rd |
Industry group Drugs | 576 out of 2,099 | 73rd |
Industry Pharmaceutical Preparations | 403 out of 1,549 | 74th |
Pay ratio
Matthew L. Sherman's Pay | $3,462,594 |
---|---|
Median Employee's Pay | $290,520 |
Pay Ratio | 12to 1 |
In 2021, the annual total compensation of Matthew L. Sherman was $3,462,594.
The annual total compensation of the median employee at Deciphera Pharmaceuticals was $290,520.
The ratio of Matthew L. Sherman's pay to the pay of median employee was therefore 12 to one.
Sherman's colleagues
We found four more compensation records of executives who worked with Matthew L. Sherman at Deciphera Pharmaceuticals in 2021.